- Recce Pharmaceuticals (RCE) expects more data to be released in the coming months from several clinical studies of its anti-infectives
- The company says first patient dosing will get underway in August for its Intravenous (I.V.) Phase I Human Clinical Trial, which is set to run for one year
- By Q4 2021, RCE expects data to begin arriving from its Topical Phase I/II Human Burns Study, with the eight-month trial recently getting underway in WA
- Around the same time, Recce says it should also begin receiving data from its SARS-CoV-2 (COVID-19) International Studies despite a recent delay
Read the Full Article on The Market Herald here
- Forums
- ASX - By Stock
- Recce Pharmaceuticals (ASX:RCE) provides updates on study timelines
RCE
recce pharmaceuticals ltd
Add to My Watchlist
0.00%
!
38.5¢

Recce Pharmaceuticals (RCE) expects more data to be released in...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
38.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $111.3M |
Open | High | Low | Value | Volume |
38.5¢ | 38.5¢ | 38.5¢ | $100 | 259 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 20015 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 50145 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20015 | 0.380 |
4 | 6125 | 0.375 |
3 | 10261 | 0.370 |
4 | 38446 | 0.365 |
2 | 71806 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 50145 | 2 |
0.395 | 261 | 1 |
0.400 | 23104 | 2 |
0.410 | 25471 | 1 |
0.435 | 5115 | 1 |
Last trade - 10.00am 31/07/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |